Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736262 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
A Phase 2 study of Urticaria Chronic, sponsored by Jasper Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 19
- Study locations
NCT06736262: Active Phase 2 study of Urticaria Chronic, sponsored by Jasper Therapeutics.
NCT06736262 is a Phase 2 study of Urticaria Chronic that is active but no longer recruiting, run by Jasper Therapeutics. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). The trial reports 19 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736262, a Phase 2 study of Urticaria Chronic, is active but no longer recruiting, sponsored by Jasper Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 19
- Study locations
Study Summary
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
Primary Outcome
Incidence and severity of AEs including SAEs, TEAEs and AEIs.
Conditions Studied
Interventions
- DRUG Briquilimab
Study Locations (19)
Maryland
- Investigative Site 101 - Baltimore
- Investigative Site 121 - White Marsh
Alabama
- Investigative Site 118 - Birmingham
Arkansas
- Investigative Site 108 - Little Rock
California
- Investigative Site 105 - San Diego
Florida
- Investigative Site 116 - Tampa
Idaho
- Investigative Site 109 - Boise
Illinois
- Investigative Site 124 - Normal
Indiana
- Investigative Site 110 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What the registry record for NCT06736262 still lists
NCT06736262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Urticaria Chronic appearing as the primary indexed condition, and to 1 intervention - of which Briquilimab is the first listed.
NCT06736262 lists 19 locations in 18 states (Maryland, Alabama, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06736262 about?
NCT06736262 is a clinical study titled "A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials". Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
What is the current status of trial NCT06736262?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2024-11-26. Estimated completion is 2026-09-30.
What conditions does trial NCT06736262 study?
This clinical trial studies the following conditions: Urticaria Chronic.
What interventions are being tested in trial NCT06736262?
The interventions under investigation include: Briquilimab (DRUG).
Who is sponsoring clinical trial NCT06736262?
This trial is sponsored by Jasper Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736262 being conducted?
This trial has 19 study locations across Alabama, Arkansas, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736262's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI